Sale of 15+ royalties on antibodies to Ligand
Selexis SA sold more then 15 biologic development programs to Ligand Pharmaceuticals Incorporated. The acquired programs are in various preclinical and clinical stages. Selexis intends to use the funds from the Ligand deal to conduct R&D to further develop the next generation of SUREtechnology Platform™ products. The Company’s SUREtechnology Platform™ is based on novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allows for higher and more stable expression of recombinant proteins. Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins.